Graft Polymer IPO: When can you buy shares of this polymer company?

3 min read | December 24, 2021 05:56 PM AEDT | By Rishika Raina

Graft Polymer IPO

Graft Polymer, which focuses on developing polymer modification and drug delivery systems, is getting ready to get its shares on the Financial Conduct Authority’s official list.

The company will allot and issue 23,255,813 new ordinary shares on admission, which is expected to become effective with the commencement of unconditional dealings on the London Stock Exchange at 8.00 am on 6 January 2022.

The company is planning to offer its ordinary shares of £0.001 each to the public at £0.215 per share to raise capital worth a gross of £5 million. After the IPO, the market value of Graft Polymer would reach approximately £22.4 million. The broker of the listing is Turner Pope Investments.

The funding raised would be channelised towards further research and development of the polymer modification technology, while the company is already providing its intellectual property (IP) to an array of sectors, ranging from healthcare to automotive.

About Graft Polymer

Established in 2017, Graft Polymer (UK) PLC focuses on its core business of developing polymer modification technology and creates products and solutions which enhance the performance, minimise the usage of raw materials, and improve the physical as well as the chemical value of the end products. The group has a research and marketing facility in Slovenia and serves a wide variety of markets. The worldwide impact modifier market was valued at approximately $3.9 billion last year.

Around three years ago, the group started with commercial sales to polymer compounders across several markets, which include medical, aerospace, automotive, construction, packaging, consumer products, and clothing. With several globally distributed partners, Graft Polymer has substantially increased its geographical footprint, covering Europe, India, and Russia. It strives for collaboration with refiners for the development of grafted products and aims to obtain more long-term orders.

GraftBio, which is a new division of the group, was launched last year for exclusively developing intellectual property targeting Bio or Pharma applications. This included providing better solutions for drug delivery systems, which have been negatively impacted during the pandemic.

Bottomline

Graft Polymer’s founder and chief executive, Victor Bolduev, said that the group is thrilled to announce its flotation on the LSE’s main market, especially during the times of rising demand for the union of environmental protection and polymer modification. He added that the IPO would potentially help the company to fund its further growth and develop IP and new products for various markets.

The impact modifier market is rapidly increasing, and as of 2020, it was valued at $3.9 billion. Graft Polymer is aiming to increase its market share in this core polymer modifier market through major distributors across the globe. Over 50 Graft Polymer products have already been launched into the market as of now.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.